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Background: Biological sample and data transfer within and out of Africa is steeped in controversy With the
H3Africa project now aiming to establish biobanks in Africa, it is essential that there are ethical and legal
governance structures in place to oversee the operation of these biobanks. Such governance is essential to
ensuring that donors are protected, that cultural perspectives are respected and that researchers have a ready
availability of ethically sourced biological samples.
Methods: A literature review of all legislation, regulations, guidelines and standard operating procedures on
informed consent, confidentiality and the transfer of biological samples amongst countries in Sub-Saharan Africa
was conducted. In addition, an examination of the websites of departments of health and national ethics
committees was performed. Researchers and research ethics scholars in the field in various African countries were
contacted for assistance. A literature review of all studies examining participants views on issues related to
biobanking in Africa was carried out and five separate studies were found.
Results: It was found that biobanking guidelines differ substantially across Sub-Saharan Africa regarding biobanking
and often conflicted across borders. This has the potential to negatively impact collaboration. Furthermore, the
guidelines in place often do not recognise the ethical difficulties arising from the transfer of biological samples and
are unsuitable to regulate biobanks. Additionally, there is insufficient research into the views of research participants
and stakeholders on the use of biological /samples.
Conclusion: Collaboration is necessary to ensure the success of biobanking projects in Africa. To achieve this, there
should be some harmonization of guidelines across Africa which would aid in transferring biological samples across
borders. These guidelines should reflect the unique ethical issues arising out of the storage and secondary uses of
biological samples. Finally, further research into the views of research participants is necessary. Such studies should
aid in the drafting of any new harmonization guidelines.Background
For decades, research has flourished in Africa and large
volumes of biological samples and data have been trans-
ferred to developed countries for storage in biobanks
and uncertain secondary use. In June 2010, the National
Institutes of Health (NIH) and the Wellcome Trust
launched a joint project called “Human Heredity and
Health in Africa” (H3Africa) [1]. This project aims to
identify the genetic and environmental factors that con-
tribute to common diseases in Africa which will ultimately
improve the health of African populations. Central to this
project is the establishment of biobanks in Africa which* Correspondence: ciara.staunton@gmail.com
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distribution, and reproduction in any mediumwill store and make available DNA, tissue samples and
medical information to researchers. This will not only im-
prove the infrastructure and promote research in Africa,
but may also lead to increased collaborations both within
Africa and across the world [2].
Once operational, the biobanks must ensure that these
materials and data are made available “in a manner consist-
ent with national legislation and ethical approvals” [3]. The
H3Africa’s High-Level Principles on Ethics, Governance
and Resource Sharing also provides guidance on informed
consent, confidentiality, the sharing of research samples,
data and protocols, providing feedback to research partici-
pants, intellectual property rights and community engage-
ment [3]. While this project should build research capacity
within Africa many jurisdictions within Africa currently doed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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stored biological samples. Furthermore as these principles
recommend a new approach to many long standing ethical
principles such as informed consent, they may be in conflict
with existing national guidance [4]. These difficulties
are further compounded by the lack of research on the
perceptions of African people on the use of their stored
biological data.
The H3Africa project is not the first initiative to establish
biobanks in Africa and a number of local and national
biobanks have emerged. The Africa Centre in South Africa
has built up an extensive collection of biological samples
over the past decade [5]. and the Gambia was the first
African country to establish a national DNA bank [6].
However, these biobanks may have emerged without formal
legal or ethical oversight. Where guidance is in existence,
disparities exist in relation to informed consent and export
and import requirements. Additionally, many institutions
may be storing samples but they may not be formal
biobanks. As the H3Africa project intends to increase the
number of biobanks across Africa, there is a need to ensure
that there are harmonious legal and ethical guidelines
on the storage of biological samples across the African
continent. While it is unlikely that there will be agreement
on the establishment of one central biobank in Africa [2].
efforts should be made to ensure that there is uniformity
of governance of biobanks throughout Africa. This will
enable easy transfer of biological samples throughout the
continent and ultimately encourage collaboration.
This growth in biobanks is echoed throughout the rest
of the world where a number of national (e.g. www.decode.
com, www.genomics.gov) and local biobanks have been
established in response to a growing need for ready access
of biological samples [7]. Despite the emergence of these
national biobanks, many large scale research projects may
need biological samples from multiple biobanks and, as
such, there should be basic quality and documentation
standards across all biobanks to ensure ease of transfer
[8]. As a result, there has been the emergence of groups
such as the Biobank and Biomolecular Resources Research
Infrastructure (BBMRI) which has as one of its aims to
create a legal and financial framework for a pan-European
biobank infrastructure [9] and the P3G (Public Population
Project in Genomics) Consortium which has members
throughout the world [8]. Despite these groups, difficulties
in international collaboration have emerged where there
are differences in guidelines [10].
Methods
Of concern, unlike international counterparts [11], there is
a paucity of studies on the opinions of research participants
in Africa on the ethical issues raised by biobanking [12]
with the only studies focusing on ethical issues encoun-
tered by Ethical Review Committees (ERCs) in Kenya [13],participants in a Nigerian study on storage and reuse [14],
two South African studies in which participants were asked
their views on storage and reuse [15,16], seeking con-
sent for genetic research in Ghana [17] and the views of
Ugandans on stored biological samples [18]. Thus to ensure
that good governance of biobanks in Africa complements
the H3Africa project, future research is required to assess
the opinions of research participants in addition to har-
monious legal and ethical guidelines throughout Africa.
In particular, focus must be given to consent procedures,
confidentially as well as the importing and exporting of bio-
logical samples. Although other issues such as the return of
research results and research and the participation of chil-
dren in biobanking are also hotly debated, the three issues
that follow will be the focus of discussion in this paper.
Results
Informed consent
The need to adequately obtain informed consent prior to
research involving human participants is a fundamental
ethical principle [19]. Its origin is rooted in the Nuremberg
Trials and is founded on the basis that individuals have the
right to decide what is done with their bodies [19] and
that any risk associated with research must be voluntarily
accepted [10]. The informed consent process has been
described as the ‘moral contract’ between the participant
and researcher as it sets out the framework though which
their biological samples may be used [14]. Thus, the
consent document should outline the purpose for which
their biological samples will be used and consent should
be sought on this basis alone [20].
The difficulty with biobanks is that the potential second-
ary uses of the samples may not be known at the time of
consent. Thus, to conform to the principle of informed
consent, participants must be re-contacted to obtain their
re-consent [14] which may potentially drastically reduce
the number of available samples [10]. Due to the onerous
and time-consuming task that this presents, it has been
suggested that the traditional understanding of informed
consent must be re-examined in light of biobanking or
risk negatively impacting population genetic research [21].
As the use of a biological sample contains little physical
risk for the participant [10] and biobanking potentially has
a potential considerable social value [22], it has been argued
that there should be a move away from a strict informed
consent doctrine in biobanking with broad consent and
tiered consent proposed as two options.
Broad consent occurs when a donor consents to the
use of their biological samples for future, unspecified re-
search. This simplifies the consent process as it negates
the need to re-contact the donor and has also received
the support of the World Health Organisation (WHO)
[23]. If the risks and information provided in the original
consent are common to several studies, then arguably
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However if no similarities exist between the studies, the
consent cannot be informed and is thus contrary to the
Declaration of Helsinki. While arguably the level of
information a person must be given before their consent
can be considered informed is uncertain, a donor cannot
possibly make an autonomous decision based on little
or no information. While admittedly there is a need
to re-examine the “one study/one informed consent”
paradigm [24] in the context of biobanking, Caulfield et al.
have argued that as broad consent is quite vague, it is too
general to have any legal weight [21].
Tiered consent provides donors with a range of con-
sent options; they may opt for broad consent, opt to be
recontacted before the sample is used, or opt for a REC
to consent on their behalf [22]. Such a model conforms
to the Organisation for Economic Development (OECD)
guidelines on Human Biobanks and Genetic Databases
which requires a review process where samples are to be
used in a manner not anticipated in the original consent
form [25]. While such a model does not do away with
the difficulties of potentially contacting all donors to
obtain their reconsent or address all the difficulties
that broad consent raises, by presenting a donor with a
range of options from which they can choose, strikes a
balance between advancing the interests of science and
respecting the autonomy of participants [26].
It would also appear that there is support in Africa for
these new models of consent. In a study examining
attitudes to biobanking in Nigeria, Igbe et al. reported that
over half the participants were in favour of broad consent,
a quarter supported some form of restricted consent and
the remaining quarter supported tiered consent. Yet, even
amongst those who supported broad consent, there was
concern that there should be some additional control
before the samples are used in research. For example,
the approval of the Nigerian Federal Ministry of Health
must be sought or safeguards be put in place to prevent
the unethical use of the samples [14]. Similarly, Wendler
et al. have found that a study in Uganda indicated a high
level of support for sample reuse based on future insti-
tutional review board (IRB) approval [18]. These findings
were echoed in a South African study which indicated,
that while participants were willing for their sample to
be used in future research, they would attach conditions
to its reuse [15].
While these are small scale studies and the findings
should not be taken as representing the views of all of
Africa, they do indicate that there is a willingness to go
beyond the traditional informed consent doctrine in the
context of biobanking. However the apparent support of
broad consent should not be taken at face value as closer
examination of the responses found that participants
would want some checks put in place to ensure that theresearch conforms to ethical norms. Under a tiered consent
model, the donor could opt that research ethics committee
(REC) approval is obtained and this would be in accordance
with the Declaration of Helsinki which states that reconsent
can only be waived upon approval of a REC. It would then
be the role of the REC to determine whether the research
can proceed or whether reconsent is necessary. If donors
wish that there is some control over the use of their sam-
ples, this additional check by the REC may prove necessary.
A review of protocols submitted to two Ethics Review
Committees in Kenya found that less than half who re-
quested the use of samples for their research contacted
the donors [13]. Yet the findings of Moodley et al. in a
small South African study have suggested that some have
reservations about RECs consenting on their behalf, with
50% of participants indicating that they would not want
a REC to consent on their behalf [16]. If this reservation
towards RECs is Africa-wide, a tiered consent model
could address this issue as the donors can opt that they
be recontacted or appoint some other body to consent
on their behalf.
In contrast to these findings, regulations in Africa tend
to focus on the traditional informed consent doctrine with
a role for the REC in secondary use. The South African
National Health Act 2003 requires informed consent before
a biological sample is donated for research. While the legis-
lation is silent as to reuse, the Ethics in Health Research
Guidelines state that each research institution should draft
guidelines as to when reconsent is required and when a
waiver of consent may be obtained [27]. National guidelines
on this issue would be preferable as otherwise institutions
may apply differing ethical principles.
In Botswana, the Standard Operating Procedures for
Biomedical Research requires donors to be given the
option of deciding whether their samples should be stored
for future use and the Health Research and Development
Committee (HRDC) must approve any protocol which
seeks to reuse the tissue samples [28]. The Gambia de-
veloped its guidelines in 2001 in response to the estab-
lishment of its National DNA bank. The guidelines do
not require the consent of the donor if the samples
have been anonymised and unlinked, but rather the
consent of the Gambia Government/MRC Laboratories
Joint Ethics Committee (the Ethics Committee). Where the
samples have not been anonymised, in principle informed
consent should be required but this may be waived by the
Ethics Committee [29].
By contrast, in Uganda, a consent form separate from
the form enrolling a participant in a study is required to
obtain and store a biological sample. This form must
detail where the sample will be stored, the purpose of
the study, how their confidentiality will be protected and
the conditions surrounding the future use of the sample.
At this point donors are given the option of deciding
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[30]. Sudan’s guidelines similarly require the consent
document to discuss whether there is the possibility of
the potential secondary use of the samples, whether
that use will be limited, the type of research which may be
carried out on the samples and the conditions under which
the donor may be contacted to authorise reuse [31].
The recently passed Zambian National Health 2013
provides for the establishment of biobanks but states that
biological material can only be collected for the manner in
which it was indicated in the research protocol. It is cur-
rently unclear whether an exception will be made for future
use for research and under what conditions the consent
can be waived. Other jurisdictions fail to give guidance.
Kenya’s National Guidelines are silent on the issue while
both Ethiopia [32] and Malawi [33] discuss the procedures
for importing and exporting samples but give no guidance
as to the consent required for future reuse.
Confidentiality
Central to good governance of biobanks is the requirement
that the confidentiality of donors be maintained. This not
only includes ensuring that access to the data is limited so
that donors cannot be identified by certain third parties,
but also that any results are kept confidential to ensure that
there is no risk of discrimination or stigmatisation. The risk
of stigmatisation and discrimination is a real concern in
genetic research and in April 2010, Arizona State University
agreed to pay $700,000 to members of the Havasupai
Indian tribe to settle claims that the improper use of the
tribe’s blood samples stigatimised the tribe [26].
The UNESCO Declaration on Human Genetic Data
requires states to protect the privacy of an individual and
the confidentiality of genetic information which is linked to
an identifiable person, family or group. To achieve this,
samples can be either anonymised whereby all indentifying
data has been removed or coded [34]. The codes may
be both double or single coded and the sample can
only be identified by breaking the unique codes of the
sample [7]. To fully understand their involvement with
the biobank, donors must know whether their sample will
be anonymised [25]. However developments in medical
informatics and bioinformatics have demonstrated that
privacy and confidentiality can no longer be guaranteed
[4] and that with genetic samples, re-identification is
possible [35]. DNA in itself is an identifier [36], thus no
matter how anonymised data is, there is the potential
that it may be identified [37].
A further problem with anonymised samples is that
it can limit the usefulness of the sample. The value of
biobanks is that it combines health and genetic data to-
gether [38] and the health data is as important as the
genetic information. While anonymonising the sample
protects the donors identity and it is thus “ethicallyand legally expedient by avoiding the possibility of re-
identifiability” [39], this limits the sample’s usefulness
as no other data can be added to it [12]. On the other
hand, if the sample is coded, the clinician can send ongoing
information via a third party who is the code key holder
and the researcher can send information to the clinician
in the same manner. Furthermore coding allows the iden-
tification of the sample and enables the donor to withdraw
at any time and also to be recontacted for secondary
use [7,40]. Anonymised samples cannot be re-identified,
preventing donors from withdrawing their sample. Thus
it has been argued that there should be a strong ethical
presumption in favour of coding as donors can retain
some control over their samples [41].
Internationally there is growing move away from
anonymonity with the WHO guidelines cautioning that
anonymity may be breached [42]. The CIOMS guidelines
also acknowledge that there are instances in which a sam-
ple may not be anonymised but in such circumstances,
they must be coded and this must be explained to the
donor during the consent process. In the US, IRB approval
for the use of coded samples in not necessary provided
the researchers cannot readily ascertain the identity of
the donor and the specimens were not collected for the
currently proposed research project [43]. Thus provided
confidentiality can be assured, coding appears to be a
suitable alternative.
In the limited African studies on this issue, confidentiality
has been raised as a concern. Fear of discrimination or
stigmatisation due to results has been expressed [14]
and it has been reported that research participants do
not always think that researchers will always act in their
best interests [15]. These are real fears particularly as
genetic discrimination may affect several generations of
genetic relatives [21]. Thus it is essential that biobanks
have policies concerning confidentiality in place and in
this way maintain the trust of the public.
Despite the growing trend towards coding, it is only the
Gambia that directly addresses the issue. The guidelines
state that, where possible, samples should be anonymonised
and unlinked. However they also state that confidentiality
can be protected through a coding system with the codes
to be held by the Head of Human Genetics, the Director
of the MRC, and the Gambian Government [29]. Despite
coding appearing to be a pragmatic response to ensuring
confidentiality in genetic research as it balances the privacy
of the donor with progress of science, no other jurisdiction
addresses this issue [40].
In contrast, the South African National Health Act 2003
requires the genetic material to be kept confidential and
the National Guidelines requires the REC overseeing the
establishment of a biobank to ensure that provisions are
made to ensure the confidentiality of the data [27]. Yet both
are silent as to whether the sample should be anonymised
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state that biological samples cannot be used unless it is
demonstrated to the REC that the patient’s “privacy and
confidentiality or anonymity are assured” but makes no
explicit mention to coding and whether this is preferred
over anonymity [31]. The rest of the African continent
appears to be silent on the issue.
Importing and exporting samples
Large scale population studies will require a large amount
of samples thus it may be necessary to transfer biological
samples across borders [22]. However, access and use
of materials is a charged issue, particularly in developing
countries where many communities are reluctant to permit
foreign researchers access to human tissues due to past
exploitation of vulnerable groups [44]. For example, in
2007 Indonesia refused to share its H5N1 samples with-
out a legally binding agreement which addresses benefit
arrangements and intellectual property rights [45]. Thus
the transfer of biological samples raise issues such as
ownership of the sample and ownership of any future
intellectual property rights arising out of future use of
the sample. More fundamentally, donors themselves may
object to the exporting of their samples, preferring them
to be stored in their home country in line with the legal
and ethical requirements there. Thus considering all the
issues previously discussed in relation to recontacting
a donor, should this consent be required prior to the
exportation of any sample?
Few studies have explored participant views on the
export of samples. A Ugandan study in which partici-
pants expressed a willingness to share their samples
with researchers in the US and UK [18]. In contrast, a
recent South African study found that participants
were concerned about sharing their samples with other
African countries as well as with developed countries
like the UK and the US [15]. There is a clear need for
further research in this area and it is unsurprising that
there have been previous calls for research into the extent
to which tissue exportation is consented to in Africa and
the extent to which communities understand the rationale
for tissue exportation [46]. This is particularly pertinent in
light of a study which indicated that the participants were
convinced that the researchers were going to sell their sam-
ples abroad. Although a deep mistrust of the researchers
was evidenced in this study, it does serve to illustrate the
lack of trust which may exist and a belief that researchers
are going to benefit through the sale of their samples [47].
Despite these concerns, the limited guidance does not
address the issue of donor consent. In South Africa, a
biological sample may not be imported or exported without
a permit issued by the Director-General. An export permit
will not be issued unless it is proven that the biological
sample was donated under the terms of the Act and thatthe sample will be used within the terms of the Act. This
would indicate that informed consent is required, but the
legislation is not only silent on the issue as to whether con-
sent is required for reuse of the sample, but there is no re-
quirement to seek the consent of the sample donor prior to
the issuance of an export permit. The National Guidelines
provide no further guidance but simply state that the REC
should review and approve the protocol under which data
and samples may be shared [27]. Due to the need to seek
REC approval, it would appear that donor consent is not
necessary and REC approval will suffice. Yet considering
Moodley et al’s study which indicated some reluctant to the
transfer of biological samples, this is an issue which must
be addressed in South Africa and likely, throughout the
African continent.
Surprisingly, the Act does not require the completion
of a Material Transfer Agreement (MTA) before a permit is
issued. In contrast, the Nigerian ethical guidelines require a
MTA detailing the use of the sample, its location, the dur-
ation of the storage and the transfer and termination of
the use of the sample. The guidelines further state that a
MTA must also be signed by all parties to the research,
but there is no requirement that the donor’s consent
be obtained prior to the exportation of the sample. The
Zambian National Research Act 2013 requires a MTA
prior to the transfer of any samples and this MTA must
describe the ownership of the materials and any intellectual
property rights arising out of the materials. Botswana
similarly requires a MTA prior to the exchange of any
biological samples. However there is no further guidance
on the procedures to be followed except that clearance shall
be granted by the HRDC.
Uganda appears to put some limits on the transfer of
samples abroad to situations when the country does not
have the capacity to perform the necessary research. In
such circumstances the transfer must be approved by the
Uganda National Council for Science and Technology, a
MTA must be signed and the applicant must be a legal resi-
dent of Uganda or affiliated to a legally recognised institu-
tion in Uganda. However there are no requirements that
the consent of the donor be obtained prior to the removal
of the sample. Similarly the Ethiopian guidelines state that a
sample may be exported if it requires research which is not
currently underway in Ethiopia or need to be rechecked by
a skilled worker and a MTA must be signed [32]. Despite
the legal and ethical issues which the transfer of biological
samples entails, there does not appear to be guidance on
this matter elsewhere in Africa (Table 1).
Discussion
Medical progress should not result in an erosion of ethical
principles. The basic idea of informed consent, emanating
from the Nuremberg trials, is that any risk associated with
a research protocol must be accepted on a voluntary basis.
Table 1 Table of sources
Organisation/Country Code/Legislation/Guideline Topics covered
OECD OECD Guidelines on Human Biobanks and Genetic
Research Databases (2009)
Privacy, confidentiality, informed consent,
re-contact, re-consent
World Medical Association Declaration of Helsinki Informed consent, re-contact, re-consent
South Africa National Health Act 2003 Informed consent, confidentiality, exporting/importing samples
Department of Health: Ethics in Health Research: Principle,
Structures and processes
Secondary use of samples, informed consent, re-contact,
re-consent, waiving of consent, confidentiality
Nigeria National Health Research Ethics Committee of Nigeria
(NHREC) National Code of Health Research Ethics 2007
Export/Importing of samples, MTAs
Kenya National Council for Science and Technology Guidelines
for Ethical Conduct of Biomedical Research Involving
Human Subjects in Kenya (2004)
Informed consent, re-contact, re-consent
Botswana Ministry of Health Standard Operating Procedures for Review
of Biomedical and Bio-behavioural research in Botswana
Informed consent, export/importing of samples/MTAs
The Gambia Guidelines of the National DNA bank, The Gambia (2001) Confidentiality, coding, anonymisation, informed consent,
re-contact, re-consent
Uganda Uganda National Council for Science and Technology
National Guidelines for Research Involving Humans as
Research Participants 2007
Informed consent, confidentiality, future use of samples,
export/importing of samples, MTAs
Zambia The National Research Act 2013 Informed consent, export/importing of samples, MTAs
Ethiopia Ethiopian Science and Technology Commission National
Health Science and Technology Council, National Research
Ethics Review Guideline 2005
Export/importing of samples, MTAs
Malawi National Health Sciences Research Committee, Policy
Requirements, Procedures and Guidelines for the Conduct
and Review of Human Genetic Research in Malawi (Sept 2012)
Export/importing of samples, MTAs
Tanzania Human DNA Regulation Act 2009 Informed consent
Sudan National Guidelines for Ethical Conduct of Research
Involving Human Subjects (2008)
Informed consent, confidentiality, privacy, secondary
use of samples
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risk seems to preclude broad consent and future consent.
However, if the risk of harm from future biomedical
research is low and sufficiently well controlled, if the par-
ticipant voluntarily accepts this level of risk, and if there is
a mechanism for withdrawal, then there is no reason why
broad consent and future consent to such studies should
not be acceptable.
The issue regarding consent in biobanking is raging
worldwide and no real consensus has yet emerged on this
issue [48]. It is clear that while consent is important and
should be an essential feature of the biobanking process,
the notion of informed consent being a core ethical
principle may need to be re-examined for biobanking.
While this article will not recommend whether specific
consent, tiered consent or broad consent should be adopted
throughout the African continent, what is important is that
there is a consistent approach to consent. Currently, South
Africa adheres to the traditional informed consent doctrine
which has been demonstrated to be problematic in the
biobanking context, while Uganda has detailed procedures
which must be satisfied prior to the storage of a sample.
Problems are likely to arise when samples are exported
throughout the continent. Can a country with strict consentprovisions import or export samples to those with no
guidelines? Uniform or similar consent provisions would
ensure that problems like this do not occur and risk dam-
aging collaborations throughout Africa. Furthermore there
is a need for future studies to determine whether donors
favour informed consent, broad consent or tiered consent.
Regulations on biobanking should reflect the findings of
these studies to ensure that biobanking research has the
support of the public.
However, regulations should also have a degree of flexibil-
ity. In the aftermath of Hurricane Sandy, it was reported
that due to power outages, freezers and incubators in which
biological samples were stored in New York stopped work-
ing. To save the samples, blocks of ice had to be manually
transported up 18 floors and over the following days the
samples were transported to different laboratories [49].
As Africa frequently experiences power outages and power
surges, measures such as this may be required to be taken
to protect the samples and ensure that they can be con-
tinued to be used. Such issues must be explained when
informed consent is sought.
The greatest risk to research participants in biobanking
rests on access to information and confidentiality [50].
Due to the potential identification from genetic material,
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ensure that confidentiality is maintained. If the identity of
donors cannot be kept confidential, the arguments in
favour of any form of broad consent weaken. While an
anonymonised sample is the best means of ensuring
privacy this limits the potential for a donor to withdraw
their sample. Thus the coding of samples is perhaps the
best policy to have in place. Irrespective of which option is
chosen, it is crucial that standardised policies are put in
place throughout Africa. Public trust in the biobank can
only be maintained with policies detailing how confidenti-
ality will be maintained. Currently there is a lack of regula-
tions on the maintenance of donor’s privacy in Africa and
this must be urgently addressed.
A further issue which needs closer examination is the
transfer of biological samples throughout Africa. It is
currently unclear whether the ethical standards of the
country exporting the sample must meet that of the host
country. To ensure that all samples have been ethically
sourced, the UK Human Tissue Authority’s Code of
Practice recommends that the importer put in place
SOPs which clearly sets out how informed consent was
obtained and how the information will be treated as
confidential. Furthermore the material must be sourced in
accordance with the ethical and legal review standards of
England, Wales and Northern Ireland [51]. Similar provi-
sions should be put in place in Africa as it is difficult to
ethically justify the importation of tissues from countries
which were not in accordance with the legal and ethical
rules of that country. The legal and ethical principles
should apply irrespective of the origin of the samples.
These are issues which must be outlined in the guidelines
and be a requirement prior to the issuance of an export
permit. Importantly, due to the intellectual property issues
which can arise in the transfer of samples, it is important
that a MTA be agreed between all parties. MTAs are im-
portant in the transfer of samples as they clearly issues such
as the secondary use of the samples, commercial use of the
samples and any liability associated with the samples [52].
This will avoid any potential future conflicts.
Conclusion
Biobanking has great potential to build research capacity
in Africa. However there is currently a lack of research
into the attitudes of research participants towards the
storage and secondary use of tissues in Africa. Due to
the new issues that biobanking raises in relation to in-
formed consent and confidentiality, further research
on both of these issues is necessary. Furthermore, new
regulations are necessary to ensure that basic legal and
ethical principles are adhered to and these regulations
must reflect the changes to basic ethical principles
such as informed consent and privacy. Not only should
these regulations be introduced at a national level, butthey must be done so in accordance with other African
nations. This may pose challenges to some countries
involved in the H3Africa initiative who must introduce
regulations concerning these issues which reflect local
cultural values, while also cognisant of the wider guidelines
underpinning the H3Africa project. Previous studies
may guide such countries in introducing new or amended
regulations, but new studies which reflect the particular
issues that the H3Africa project brings are necessary be-
fore such regulations are introduced. Such an approach
should help in the introduction of a harmonious legal
regime throughout Africa which will ensure an ease of
transfer of samples throughout Africa. Indeed a harmoni-
ous legislation throughout the world would be preferable
as this would increase worldwide sample sharing and
improve collaboration. However, as the H3Africa pro-
ject is specifically focused on Africa, it is necessary that
particular focus is given to ensuring a harmonious regime
in Africa first as this will ultimately benefit collaboration
and the H3Africa initiative.
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